Peter Thiel is totally incorrect about Alzheimer’s

The New York Occasions ran a lengthy interview this morning between columnist Ross Douthat and enterprise capitalist and PayPal founder Peter Thiel. There is a purpose it was revealed within the opinion part.

Thiel, a Trump booster whose allies — together with Vice President JD Vance — now litter the White Home, was given free reign to debate quite a lot of matters throughout over an hour of softball questions. Is Greta Thunberg the literal antichrist? Are the three predominant ideological colleges in Europe environmentalism, “Islamic Shariah regulation” and “Chinese language Communist totalitarian takeover”? Is AI “woke” and able to following Elon Musk to Mars? Peter appears to assume so! Maybe the “simply asking questions” faculty of journalism may add “hey, what the fuck are you speaking about” to its repertoire.

Admittedly, many of those assertions fall squarely into the realm of issues that exist inside Thiel’s thoughts palace somewhat than verifiable info, with no less than one notable exception. Comparatively early of their chat, Peter tells Ross the next [emphasis ours]:

It is a fairly daring declare! It is also utterly unfaithful.

“There was no therapy 40 or 50 years in the past for Alzheimer’s illness,” Sterling Johnson, a professor of Geriatrics and Gerontology on the College of Wisconsin, Madison, advised Engadget. “What we have been capable of do within the final 20 years has been really fairly extraordinary. We have developed markers that assist us determine when this illness begins, utilizing the utilizing amyloid markers and tau biomarkers, we all know that the illness really begins 20 years earlier than the signs do, and that may be a vital factor to know if we’re going to forestall this illness.”

In the meanwhile, Alzheimer’s stays incurable. However the absence of a miracle remedy doesn’t negate the accomplishments up to now in detection and prevention. “The primary therapies had been these window dressing therapies. It is like treating the signs such as you would deal with a chilly […] The primary technology of amyloid remedy was that sort of strategy the place it simply addressed the signs by amping up the neurons and rising the neurotransmitters obtainable to the to the mind cells.” Johnson, whose staff runs one of many largest and longest studies on individuals in danger for creating Alzheimer’s illness, added, “Now we now have alternatives to truly modify the illness biology via the amyloid pathway, but additionally we’re centered on the opposite proteinopathy — which is tau — and there is scientific trials underway.”

Thiel, a widely known advocate for developments in radical life extension (together with a reported curiosity in injecting himself with the blood of younger individuals) sees the state of scientific analysis on this space as sluggish and danger averse. However the groundbreaking work is occurring at this second. Professor Johnson pointed to a monoclonal antibody known as gantenerumab. In an early check of 73 members with inherited mutations that will trigger them to overproduce amyloid within the mind, it lower the variety of members who developed Alzheimer’s signs virtually in half. “The large section three prevention trials [of gantenerumab] are taking place proper now.”

For somebody who fashions himself as a heterodox thinker, Thiel actually appears to have came across a remarkably comparable speaking level to present Trump administration FDA head Robert F Kennedy Jr. “Alzheimer’s is a really, superb instance of how [National Institute of Health] has gone off the rails over the previous 20 years in the past with analysis on amyloid plaques” Kennedy said at a Division of Well being budgetary listening to final month. He claimed the NIH was “chopping off some other speculation” on account of “corruption.”

Unsurprisingly, the Alzheimer’s Affiliation has known as this “demonstrably false.”

“In actuality, over the newest 10 years obtainable (2014-2023), less than 14% of latest Nationwide Institutes of Well being (NIH) Alzheimer’s initiatives centered on amyloid beta because the therapeutic goal,” the group wrote, “As of September 2024, the National Institute on Aging was investing in 495 pharmacological and non-pharmacological trials. To state that Alzheimer’s analysis is targeted on amyloid to the exclusion of different targets is clearly incorrect.”

If I, personally, needed extra sturdy medical analysis and an opportunity an everlasting life (I do not), greasing the wheels of an administration broadly gutting funding for science could be a wierd approach to make that occur. However that is the kind of incoherence we have come to count on from tech oligarchs: they are saying what advantages them, even when it is nonsense on its face, even when a second’s reflection reveals it to be patently false. What’s embarrassing is the paper of file giving them free reign to do it.